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Accepted 19 May 2015; Published online 4 June 2015AbstractObjectives: To investigate the frequency of interim analyses, stopping rules, and data safety and monitoring boards (DSMBs) in pro-
tocols of randomized controlled trials (RCTs); to examine these features across different reasons for trial discontinuation; and to identify
discrepancies in reporting between protocols and publications.
Study Design and Setting: We used data from a cohort of RCT protocols approved between 2000 and 2003 by six research ethics
committees in Switzerland, Germany, and Canada.
Results: Of 894 RCT protocols, 289 prespecified interim analyses (32.3%), 153 stopping rules (17.1%), and 257 DSMBs (28.7%).
Overall, 249 of 894 RCTs (27.9%) were prematurely discontinued; mostly due to reasons such as poor recruitment, administrative reasons,
or unexpected harm. Forty-six of 249 RCTs (18.4%) were discontinued due to early benefit or futility; of those, 37 (80.4%) were stopped
outside a formal interim analysis or stopping rule. Of 515 published RCTs, there were discrepancies between protocols and publications for
interim analyses (21.1%), stopping rules (14.4%), and DSMBs (19.6%).
Conclusion: Two-thirds of RCT protocols did not consider interim analyses, stopping rules, or DSMBs. Most RCTs discontinued for
early benefit or futility were stopped without a prespecified mechanism. When assessing trial manuscripts, journals should require access to
the protocol.  2016 Elsevier Inc. All rights reserved.
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Randomized controlled trials (RCTs) are widely
accepted as the principal research method for the assess-
ment of health care interventions [1,2]. Stopping RCTsEthical approval: The participating Research Ethics Committees
approved the study or explicitly stated that no ethical approval was
necessary.
http://dx.doi.org/10.1016/j.jclinepi.2015.05.023
0895-4356/ 2016 Elsevier Inc. All rights reserved.prematurely for benefit, harm, futility, or other reasons
(e.g., slow recruitment of participants) requires consider-
ation of ethical, statistical, and logistical issues [3e6]. Pre-
planned interim analyses, stopping rules, and the presence
of a data safety and monitoring board (DSMB) are means* Corresponding author: Tel.: þ41-0-61-265-3100; fax: þ41-0-61-
265-3109.
E-mail address: matthias.briel@usb.ch (M. Briel).
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 Two-thirds of randomized controlled trial (RCT)
protocols did not consider interim analyses, stop-
ping rules, or data safety and monitoring boards
(DSMBs).
 Discrepancies in the reporting of interim analyses,
stopping rules, and DSMBs between protocols and
publications were common.
 More than 80% (37 of 46) of RCTs discontinued
for benefit or futility were stopped outside a match-
ing interim analysis or stopping rule.
 Interim analysis plans, stopping guides, and
DSMBs increase transparency and credibility when
trials are stopped early. Their adequate reporting in
both protocols (according to Standard Protocol
Items Recommendations for Interventional Trial)
and publications (according to Consolidated Stan-
dards of Reporting Trial) should be required.
to increase transparency and credibility of decision making
during the course of RCTs, in particular with respect to pre-
mature trial discontinuation. The Consolidated Standards of
Reporting Trials (CONSORT) statement recommends re-
porting of the timing of interim analyses, conditions
required for initiating interim analyses, the number of ana-
lyses, whether they were planned or ad hoc, the presence of
a priori stopping rules, and if an independent DSMB was in
place [1]. Investigators planning interim analyses should
document such plans in their trial protocols, including pre-
specification of the statistical approach used to judge the
possible need for premature discontinuation [4]. Since
2002, several regulatory guidelines about DSMBs have
been published [7e11]. DSMBs should keep interim trial
data confidential, and statistical criteria (stopping rules)
should be treated as guidelines rather than strict rules for
stopping early [12].
Little is known about the frequency of planned interim
analyses and stopping rules in protocols or about the pro-
portion of RCTs overseen by independent DSMBs. It also
remains uncertain whether such plans have an impact on
RCT discontinuation. In a cohort of RCT protocols
approved by research ethics committees (RECs) between
2000 and 2003 (before most regulatory guidelines about
DSMBs), we investigated (1) the prevalence of planned
and reported interim analyses, stopping rules, and DSMBs
in RCTs from various medical fields; (2) the association of
these features with other trial characteristics; (3) these fea-
tures across different reasons for trial discontinuation; and
(4) discrepancies between planning of interim analyses,
stopping rules, and DSMBs in RCT protocols and reporting
in corresponding journal publications.
M. Stegert et al. / Journal of Clin2. Methods
2.1. Study design
This is a planned substudy of an international, multicenter
cohort ofRCTprotocols approvedby sixRECs inSwitzerland
(Basel, Lucerne, Lausanne, and Zurich), Germany (Freiburg)
,and Canada (Hamilton, Ontario) between 2000 and 2003.
The rationale and design of the retrospective cohort as well
as other results have previously been published [13,14].
2.2. Eligibility criteria for protocols and corresponding
publications
In the present study, we included RCT protocols regard-
less of publication status. We excluded protocols of RCTs
that (1) compared different doses or routes of administration
of the same drug (dose-finding studies), (2) enrolled only
healthy volunteers, (3) were never started, or (4) were still
ongoing as of April 2013. For the analysis of reporting, we
included only full (peer-reviewed) journal publications cor-
responding to included RCT protocols. Any other formats
such as research letters, letters to the editor, or conference ab-
stracts were excluded.
2.3. Search for publications and data extraction
If the REC files provided no information about the pub-
lication status of a trial, we conducted comprehensive
searches of electronic databases (MEDLINE, EMBASE,
Google Scholar, Cochrane CENTRAL register of clinical
trials, trial registries such as ClincialTrials.gov and regis-
tries of sponsors, if publicly available) to find any associ-
ated publications [13]. If trial publication or completion
status still remained unclear, the REC in charge conducted
a survey of investigators by sending them a standardized
questionnaire (see Appendix at www.jclinepi.com). The
response rate was 80.3%; 240 of 299 investigators returned
the questionnaire [14].
Twelve investigators trained in clinical research method-
ology independently extracted data from eligible trial pro-
tocols including study design, number of centers, clinical
field, details about the intervention arms, trial funding
and initiation, planned sample size, follow-up time, and
planned statistical analyses [13]. The initial 30% of the pro-
tocol extractions were completed in duplicate. Twenty-two
investigators trained in clinical research methodology, inde-
pendently and in duplicate, extracted data from all corre-
sponding publications. Any disagreements were resolved
by consensus or third party adjudication. We used a Web-
based password-protected database for all data abstraction
(Squiekero, www.squiekero.org).
2.4. Definitions
We considered an RCT discontinued if the investigators
indicated discontinuation with a reason in their correspon-
dencewith theREC, in a journal publication, or their response
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discontinuation or if poor participant recruitment was
mentioned, we used a prespecified cutoff of less than 90%
of achieved target sample size to determine discontinuation
[13,14]. We considered a trial as discontinued based on a pre-
specified stopping rule if the reported reason for discontinua-
tion matched the purpose of a planned interim analysis or
stopping rule mentioned in the protocol. We defined an RCT
protocol as having at least one interim analysis if it explicitly
mentioned an interim analysis; and we defined an RCT proto-
col as having a stopping rule if it explicitly mentioned the use
of a statistical rule or numerical threshold to checkwhether the
trial should be stopped prematurely (e.g., O’Brien-Fleming,
alpha spending function, conditional power, and so forth).
Reviewers classified RCT protocols as industry sponsored
or investigator sponsored if the protocol clearly named the
sponsor, displayed a company or institution logo prominently,
mentioned industry affiliations for protocol authors, included
statements about data ownership or publication rights, or state-
ments about full funding by industry or public funding
agencies [14,15]. Disagreements were resolved by consensus.
2.5. Statistical analysis
For binary data, we summarized results as frequencies
and proportions and for continuous data as medians and in-
terquartile ranges (IQRs). For comparison of proportions,
we used the chi-squared test with continuity correction.
We considered two data sets: (1) all RCT protocols
involving patients (n 5 894) and (2) the subgroup of RCT
protocols involving patients with their corresponding publi-
cations (n 5 515) to investigate discrepancies in the report-
ing of interim analyses, stopping rules, and DSMBs (Fig. 1).
We used three multivariable logistic regression models
to investigate the association between RCT characteristics
(independent variables) and the three outcomes: (1) interimFig. 1. Study flow. RCT, randomized controlled trial; REC, research
ethics committee. *Number of protocols at each study center (collab-
orating REC): Basel (CH): 221; Freiburg (DE): 272; Lausanne (CH):
149; Lucerne (CH): 31; Hamilton (CA): 178; and Z€urich (CH): 43.
At Z€urich, we only extracted RCT protocols from a subsidiary research
ethics committee responsible for pediatric and surgical trials.analyses (planned vs. not planned), (2) stopping rules
(specified vs. not specified), and (3) DSMBs (appointed
vs. not appointed) according to protocols. RCT characteris-
tics included: length of follow-up (in years as continuous
variable), sample size (in increments of 100), sponsorship
(industry vs. investigator), number of centers (single center
vs. multicentre), national vs. international, medical field
(oncology, cardiovascular, infectious disease, and other),
and type of control intervention (placebo/no intervention
vs. active intervention). We calculated unadjusted and
adjusted odds ratios (ORs) with 95% confidence intervals
(CIs). We conducted a sensitivity analysis omitting length
of follow-up as an independent variable in the regression
models because of many missing values.
To investigate the association between premature trial
discontinuation for early benefit or futility and the presence
of interim analyses or stopping rules and DSMBs adjusted
for other trial characteristics, we used a multivariable
analysis with early discontinuation for benefit or futility
(yes vs. no) as the dependent variable and the following in-
dependent variables: interim analysis OR stopping rule
(planned vs. not planned), presence of a DSMB (yes vs.
no), length of follow-up (in years as continuous variable),
sample size (in increments of 100), sponsorship (industry
vs. investigator), number of centers (single center vs. multi-
center), national vs. international. This analysis was carried
out in a subsample including only RCTs discontinued for
early benefit or futility and completed trials (sample
N 5 303). RCTs discontinued for other reasons than early
benefit or futility were excluded because interim analyses
or stopping rules for unexpected events are not plausible;
in addition, we excluded RCTs with unclear completion
status and RCTs planning an interim analysis only as part
of an adaptive design, for sample size recalculation pur-
poses only, or for other reasons without a stopping mecha-
nism. Again, in a sensitivity analysis, we dropped length of
follow-up from the model due to 286 missing values (in-
crease in sample size from N 5 303 to N 5 577).
The goodness of fit of statistical models was evaluated
using the Akaike information criterion [16]. The fit of the
models did not improve by adding the participating REC
as a random effect in a multilevel model; therefore, we
omitted the random effect.
To investigate the agreement between protocols and
publications with respect to the reporting of interim ana-
lyses, stopping rules, and DSMBs, we calculated (1) the
crude agreement rate (in percent) and (2) the chance-
corrected agreement (Cohen’s kappa) [15,17]. All ana-
lyses were performed using R version 3.0.1 (www.
r-project.org).3. Results
Between 2000 and 2003, six participating RECs in
Switzerland, Germany, and Canada approved 949 RCT
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were never started and 10 that were still ongoing at the time
of analysis (April 2013) were excluded. We therefore
included 894 RCT protocols of which 515 (57.6%) were
published in one or more full journal articles. Most trials
were multicenter, industry-sponsored, parallel group RCTs
with a pharmacological intervention as experimental arm
(Table 1). The median planned sample size was 260 partic-
ipants (IQR, 100e610) and the median follow-up 0.5 years
(IQR, 0.2e1.5).3.1. Planning of interim analyses, stopping rules, and
DSMBs
Of 894 RCT protocols, 289 specified interim analyses
(32.3%), 153 stopping rules (17.1%), and 257 (28.7%)
mentioned the presence of a DSMB (Table 2). More than
one interim analysis was planned for 103 RCTs (11.5%).
The most frequently reported purposes for planned interim
analyses were early benefit (170 of 894; 19.0%) and harmTable 1. Characteristics of included RCT protocols by completion status
Characteristics Discontinued (N [ 249) (%) Com
Study design
Parallel 235 (94.4)
Crossover 12 (4.8)
Factorial 2 (0.8)
Unclear 0
Planned centers
Multicenter 195 (78.3)
Single center 54 (21.7)
Unclear 0
Trial setting
National 117 (47)
International 127 (51)
Unclear 5 (2.0)
Type of control interventiona
No active treatment/standard care 65 (26.1)
Active drug/other treatment 113 (45.4)
Placebo/sham procedure 88 (35.3)
Trial sponsorship
Industry 119 (47.8)
Investigator 130 (52.2)
Clinical area
Oncology 47 (18.9)
Cardiovascular 23 (9.2)
Infectious disease 19 (7.6)
Otherb 160 (64.3)
Planned sample size
Median (IQR) 200 (90e530)
Planned follow-up time (yr)
Median (IQR) 0.52 (0.25e2)
Not reported 133 (53.4)
Abbreviations: RCT, randomized controlled trial; IQR, interquartile rang
Values are frequencies (column percentages) unless otherwise specified
a Categories were not mutually exclusive; it was possible to select seve
b Includes pediatrics, surgery, and 20 different medical specialties each
Table 1 at www.jclinepi.com.
c Missing data for target sample size in 12 protocols.
d 18 of 459 RCTs without reported follow-up time had a time to event(133 of 894; 14.9%; Appendix Table 3 at www.jclinepi.
com). Details about the planned DSMBs such as composi-
tion or blinding status were rarely provided. Almost all
RCT protocols for which a stopping rule was planned
[149 of 153 (99.6%)], also mentioned interim analyses
(Appendix Table 2 at www.jclinepi.com). Both an interim
analysis and a DSMB were planned in 164 of 894 RCTs
(18.3%), and there were 125 of 894 RCT protocols
(14.0%) that described an interim analysis but no DSMB.
There were 100 of 894 RCT protocols (11.2%) mentioning
all three features, whereas 509 of 894 (56.9%) mentioned
none. Most of the 249 discontinued RCTs [139 (55.8%)]
did not plan any form of early stopping mechanism (interim
analysis, stopping rule, or DSMB).
In multivariable logistic regression, we investigated the
association of interrelated trial characteristics with the plan-
ning of interim analyses, stopping rules, and DSMBs
(Appendix Tables 4 and 5 at www.jclinepi.com). Results
suggested that longer follow-up, larger planned sample
size, and multicenter status in RCTs were independentlypleted (N [ 575) (%) Unclear (N [ 70) (%) All (N [ 894) (%)
534 (92.9) 67 (95.7) 836 (93.5)
27 (4.7) 2 (2.9) 41 (4.6)
13 (2.3) 0 15 (1.7)
1 (0.3) 1 (1.4) 2 (0.2)
496 (86.3) 50 (71.4) 741 (82.9)
75 (13) 20 (28.6) 149 (16.7)
4 (0.7) 0 4 (0.4)
155 (26.9) 37 (52.8) 309 (34.5)
401 (69.7) 27 (3.8) 555 (62.1)
19 (3.3) 6 (8.6) 30 (3.4)
122 (21.2) 18 (25.7) 205 (22.9)
282 (49) 39 (55.7) 434 (48.5)
240 (41.7) 18 (25.7) 346 (38.7)
394 (68.5) 38 (54.3) 551 (61.6)
181 (31.5) 32 (45.7) 343 (38.4)
92 (16) 8 (11.4) 147 (16.4)
78 (13.6) 6 (8.6) 107 (12.0)
45 (7.8) 12 (17.1) 76 (8.5)
360 (62.6) 44 (62.9) 564 (63.1)
330 (120e735) 150 (78e300) 260 (100e610)c
0.5 (0.23e1.5) 0.3 (0.08e1) 0.5 (0.23e1.5)
279 (48.5) 47 (67.1) 459 (51.3)d
e.
.
ral options for one RCT.
representing!7% of the total. A complete list is provided in Appendix
analysis.
Table 2. Information on interim analyses, stopping rules, and DSMBs in RCT protocols by completion status
Characteristics
Discontinued
(N [ 249) (%)
Completed
(N [ 575) (%)
Unclear
(N [ 70) (%)
All
(N [ 894) (%)
Interim analysis planned 88 (35.3) 180 (31.3) 21 (30) 289 (32.3)
Interim period definition
After a certain number of recruited patients 46 (18.5) 86 (15.0) 15 (21.4) 147 (16.4)
After a specific interval 13 (5.2) 34 (5.9) 4 (5.7) 51 (5.7)
After reaching a specific number of events 10 (4) 26 (4.5) 0 36 (4)
At least two of the above three 5 (2) 18 (3.1) 1 (1.4) 24 (2.7)
After every event or patient 0 2 (0.3) 0 2 (0.2)
Other 0 2 (0.3) 1 (1.4) 3 (0.3)
Not reported 14 (5.6) 12 (2.1) 0 26 (2.9)
Number of planned interim analyses
1 53 (21.3) 100 (17.4) 10 (14.3) 163 (18.2)
2 18 (7.2) 35 (6.0) 2 (2.9) 55 (6.2)
3 4 (1.6) 17 (3.0) 4 (5.7) 25 (2.8)
4 4 (1.6) 15 (2.6) 4 (5.7) 23 (2.6)
Not reported 9 (3.6) 13 (2.3) 1 (1.4) 23 (2.6)
Stopping rule defined 51 (20.5) 96 (16.7) 6 (8.6) 153 (17.1)
DSMB planned 63 (25.3) 181 (31.5) 13 (18.6) 257 (28.7)
Blinding status
Blind 8 (3.2) 32 (5.6) 3 (4.3) 43 (4.8)
Definitely not blind 14 (5.6) 47 (8.2) 5 (7.1) 66 (7.4)
Unclear 41 (16.5) 102 (17.7) 5 (7.1) 148 (16.6)
Information on composition of DSMB
Member expertise provided 10 (4) 47 (8.2) 3 (4.3) 60 (6.7)
Member names provided 5 (2.0) 11 (1.9) 1 (1.4) 17 (1.9)
Member affiliation provided 2 (0.8) 0 1 (1.4) 3 (0.3)
Two of above three 6 (2.4) 17 (2.9) 1 (1.4) 24 (2.7)
All of above three 6 (2.4) 10 (1.7) 0 16 (1.8)
No information provided 32 (12.9) 81 (14) 6 (8.6) 119 (13.3)
Sponsor representative was member 4 (1.6) 24 (4.2) 2 (2.8) 30 (3.4)
Abbreviations: DSMB, data safety and monitoring board; RCT, randomized controlled trial.
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rules, and DSMBs. Trials conducted in oncology compared
with other clinical areas and investigator-sponsored trials
(vs. industry-sponsored) more often planned interim ana-
lyses and stopping rules (analysis adjusted for other exam-
ined trial characteristics). We found a similar pattern for
discontinued RCTs only, that is, discontinued RCTs
without a preplanned stopping mechanism were on average
smaller, mostly investigator-sponsored and single-center
trials (Appendix Table 6 at www.jclinepi.com).3.2. Association of premature discontinuation with
interim analyses, stopping rules, and DSMBs
Of 249 discontinued RCTs, poor recruitment was the
most frequent reason for discontinuation; 70 RCTs were
primarily discontinued for harm, early benefit, or futility
(Table 3). For 15 of 70 RCTs (21.4%), the protocol
mentioned the purpose of the interim analysis that matched
the actual reason for trial discontinuation (6 of 24 for harm,
5 of 9 for early benefit, and 4 of 37 for futility). When we
leave aside the RCTs discontinued for harm (because stop-
ping in case of unexpected harm is exactly what responsible
investigators and expert DSMBs should do), we still note
that 46 RCTs were discontinued for early benefit or futility,
of which 37 (80.4%) were stopped outside a formal interimanalysis. A multivariable regression analysis that included
only RCTs discontinued for early benefit or futility and
completed trials showed that RCTs discontinued for early
benefit or futility more often planned any interim analysis
or stopping rule in their protocol than completed RCTs
(adjusted OR, 3.74; 95% CI: 1.1, 12.7; Appendix Table 7
at www.jclinepi.com). However, the purpose of the interim
analysis or stopping rule in the protocol did most of the
time not match the actual reason for discontinuation.3.3. Agreement between protocols and publications
Of 515 published RCTs, 132 (25.6%) reported interim
analyses, 66 (12.8%) a stopping rule, and 147 (28.5%) a
DSMB. Of 132 publications reporting an interim analysis,
33 (25.0%) did not specify its purpose. In protocols, the
proportion of planned interim analysis with no reported
purpose tended to be smaller [32 of 289 (11.1%);
Appendix Table 3 at www.jclinepi.com]. Both interim anal-
ysis and DSMB were reported in 92 of 515 publications
(17.9%). All three (i.e., interim analyses, stopping rule,
and DSMB) were reported in 47 (9.1%).
The crude agreement between planning in protocols and
reporting in publications was for interim analyses 78.9%,
for stopping rules 85.6%, and for DSMBs 80.4%
(Appendix Table 8 at www.jclinepi.com). Planning an
Table 3. Planned DSMBs, interim analyses, or stopping rules in RCT protocols by completion status and reasons of discontinuation
Trial status All (N [ 894) (%) Planned DSMBa (%)
Planned interim analysis or stopping
rulea (%)
Completed 575 (64.3) 181 (31.5) 186 (32.3)
Unclear 70 (7.8) 13 (18.6) 21 (30)
Discontinued 249 (27.9) 63 (25.3) 88 (35.3)
Poor recruitmentb 100 (11.2) 18 (18.0) 27 (27.0)
Futilityc 37 (4.1) 14 (37.8) 26 (70.2)
Administrative reasonsd 36 (4.0) 8 (22.2) 8 (22.2)
Harm 24 (2.7) 11 (45.8) 11 (45.8)
Unknown reasone 24 (2.7) 3 (12.5) 5 (20.8)
Benefit 9 (1.0) 2 (22.2) 7 (77.8)
External evidence 8 (0.9) 4 (50) 2 (25)
Lack of funding 5 (0.6) 1 (20) 1 (20)
Other 6 (0.7) 1 (16.6) 0
Abbreviations: DSMB, data safety and monitoring board.
a Columns include numbers and row percentages.
b Some trials had an additional reason for discontinuation: benefit (n 5 1), futility (n 5 2), and other reasons (n 5 3).
c Includes randomized trials with adaptive designs that have been stopped after the first (n 5 5) or second stage (n 5 1).
d Includes strategic decisions from companies, consequence of new requirements from regulatory bodies, and change of workplace of principal
investigators.
e Reason for not achieving 90% of target sample size remained unclear.
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lication occurred in 80 (15.5%) of 515 RCTs and was more
common than reporting an interim analysis in the publication
without corresponding documentation in the protocol, which
happened in 29 (5.6%) of 515 RCTs. The chance-corrected
agreement between protocols and publications was moderate
with Cohen’s kappa values of 0.51 (95% CI: 0.43, 0.59) for
the reporting of interim analyses, 0.47 (95% CI: 0.37, 0.57)
for stopping rules, and 0.55 (95%CI: 0.47, 0.63) for DSMBs.
Of 103 RCTs reporting an interim analysis in both pro-
tocol and publication, 32 (31.1%) reported discrepant
numbers of interim analyses, 55 (53.4%) reported consis-
tent numbers, and 16 (15.5%) did not specify the number
of interim analyses. In 70 RCTs (68.0%), the purpose of
interim analyses was reported consistently in protocols
and publications; there were discrepancies in the remaining
33 RCTs (32.0%).
All nine RCTs discontinued for early benefit and 18 of the
37 RCTs discontinued for futility were published as full jour-
nal articles. Of the nine publications ofRCTs discontinued for
early benefit, six mentioned a prespecified stopping mecha-
nism, and three did not. Furthermore, for twoRCTs discontin-
ued for early benefit, a DSMB was specified in the protocol,
whereas for three RCTs, a DSMB was mentioned in the pub-
lication. Of the 18 publications of RCTs discontinued for fu-
tility, 16 mentioned that the RCT was prematurely
discontinued and 9 explicitly stated that the trial discontinua-
tion was based on the recommendation of a DSMB.4. Discussion
4.1. Main findings
We found that 32% of RCT protocols planned one or
more interim analyses, 17% specified stopping rules, and29% planned a DSMB. These design features were inde-
pendently more common in RCT protocols with longer
follow-up, multicenter status, and larger sample size and
in oncology rather than other specialties. Of all started pa-
tient RCTs, 28% were discontinued prematurely; mostly
due to unexpected reasons (poor recruitment, administra-
tive reasons, and unexpected harm). Only 5% (46 of 894)
of RCTs were discontinued for early benefit or futility.
More than 80% of those (37 of 46) were stopped outside
a formal interim analysis or stopping rule. Approximately
20% of the 515 published RCTs had discrepant reporting
between protocols and publications for the presence of
interim analyses, stopping rules, or DSMBs; chance-
corrected agreement was moderate.4.2. Strengths and limitations
The present analyses were part of a larger project inves-
tigating the prevalence and publication of discontinued
RCTs in an international, multicenter cohort of RCT proto-
cols across all medical fields [13,14]. We worked in close
collaboration with RECs and had unrestricted access to
their archived RCT protocols and corresponding files. We
involved only trained methodologists in data abstraction
and considered only a limited number of variables in the
statistical models to minimize spurious associations. We
allowed for a long follow-up period (10e13 years) between
protocol approval and our last search for corresponding
publications (April 2013) to maximize the number of pub-
lished RCTs.
On the other hand, the long follow-up time may repre-
sent a limitation of our study. The included protocols from
2000 to 2003 might no longer reflect current practices of
planning interim analyses, stopping rules, and DSMBs
because in the meantime considerable efforts have been
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regulatory guidelines [7e11,18]. A further limitation of
our study was that we extracted only 30% of the protocol
data in duplicate due to limited resources, that is, we used
single data extraction for 70% of the protocol data poten-
tially increasing extraction errors [14]. However, we used
piloted extraction forms with detailed written instructions,
conducted formal calibration exercises with all data extrac-
tors, and checked extractions from a random sample of pro-
tocols at several points during the process. Agreement was
good, with no more than two discrepancies among 30
extracted variables [14]. A second investigator verified all
data regarding discontinuation and publication of RCTs.
The suboptimal quality of information found in protocols,
in particular those of investigator-sponsored trials, limited
our ability to extract details regarding interim analyses,
stopping rules, and DSMBs or other trial characteristics
such as trial phase. For many included RCTs, lack of clarity
regarding the length of follow-up substantially limited the
number of protocols without missing data for our regression
analyses. All regression analyses were post hoc, and
although sensitivity analyses omitting length of follow-up
yielded similar results, findings should be interpreted
cautiously.4.3. Comparison with other studies
Most previous research addressing the use of interim
analyses, stopping rules, and DSMBs has been based on
data from RCT publications without taking into account
whether trials were discontinued or completed
[6,7,19e21]. One exception, a study by Chan et al. [22]
comparing 70 protocols approved by a REC in Denmark
with corresponding publications, reported that 13 (18%)
mentioned interim analyses in protocols, but only 5
(7%) were mentioned in corresponding publications
[22]. We found results similar to Chan et al., including
a lower reporting rate of interim analyses in publications
(26%) than in protocols (35%).
In a cross-sectional study including RCTs published in
2000 in 24 high-impact general medical and specialist jour-
nals, Sydes et al. found that interim analyses were reported
in 107 (16%) and DSMBs in 120 (18%) of 662 trials. In the
same study, 58 fo 150 RCTs (39%) reporting a DSMB and/
or interim analyses also described a statistical stopping rule
[19]. Another study included 1,772 RCTs published in
eight major general medical and specialist journals between
2000 and 2005; 586 (33%) reported an interim analysis and
470 (27%) a DSMB [20]. This study found that reporting of
both interim analyses and DSMBs increased from 2000 to
2005. These may also explain the higher prevalence of
interim analyses (26%) and DSMBs (29%) in our study,
in which most of the 515 RCTs were published after
2005; Sydes et al. [19] examined RCTs published in
2000, and Chan et al. [22] included RCT protocols that
were approved during 1994e95.Similar to Sydes et al. [19], we found a positive associ-
ation of DSMB presence with multicenter study design,
larger sample size, and trials including a placebo arm. In
addition, we showed that these trial characteristics were
also associated with the use of interim analyses.4.4. Implications
To decide if results from a particular RCTare trustworthy,
clinicians and policy makers need to know whether interim
analyses, stopping rules, or DSMBs were planned. Our study
suggests that among RCTs discontinued for early benefit or
futility, few mentioned a matching interim analysis or stop-
ping rule in the protocol. DSMBs can help to increase trans-
parency and credibility of the decision making during the
course of RCTs, in particular with respect to early discontin-
uation. However, we found that only about a third of RCTs
discontinued for early benefit or futility mentioned a DSMB
in their protocol. This raises the possibility that many RCTs
were discontinued after review of interim results, thus poten-
tially introducing substantial bias. Most trialists did not
inform readers about whether and how often they had
planned to review outcome data or actually did so.
The concept of stopping for harm refers to both formal
inferiority of a tested intervention compared with a reference
intervention and unexpected safety concerns. In our cohort,
of the 24 RCTs stopped early for harm, we found six corre-
sponding protocols with a matching interim analysis or stop-
ping rule, but we noted that of the 12 published RCTs
discontinued for harm, 11 were actually stopped due to unex-
pected safety concerns. As Pocock [23] argues ‘‘it is gener-
ally difficult to define formal statistical guidelines when it
comes to the plethora of potential safety problems that a
new treatment might give rise to.’’ We should not draw any
inferences from the small number of matching prespecified
interim analyses and stopping rules in RCTs discontinued
for harm because picking up unexpected safety problems
when looking at all the available information is how an expert
DSMB should function. However, with RCTs discontinued
for harm, it is of concern that less than half of protocols
(46%) mention a DSMB in the first place and only half
(50%) are fully published RCTs.
Initiatives to improve the quality of RCT protocols such
as the Standard Protocol Items Recommendations for Inter-
ventional Trials are urgently needed and should be
endorsed by both RECs and funding agencies [11]. Simi-
larly, the CONSORT statement for RCT reports, first issued
in 1996 and updated last in 2010, could be used more effec-
tively by academic institutions and journals to inform the
research community about important design features of tri-
als in a transparent and standardized manner [1]. Our re-
sults are based on protocols from 2000 to 2003, and
practices might have changed over time; future research
will need to examine whether updated or new reporting
guidelines actually improved the planning and reporting
of interim analyses, stopping rules, and DSMBs over the
159M. Stegert et al. / Journal of Clinical Epidemiology 69 (2016) 152e160last decade. As a simple measure, we suggest that investi-
gators routinely submit their RCT protocol together with
the manuscript reporting results to a journal (unless the pro-
tocol has already been published) and that editors and peer-
reviewers consider both documents together.5. Conclusions
This empirical study found that of 894 RCT protocols
approved by one of six RECs between 2000 and 2003,
two-thirds did not consider interim analyses, stopping rules,
or DSMBs. Five percent of RCTs were discontinued for
early benefit or futility, and most of these stopped without
a formal mechanism specified in the protocol. Discrep-
ancies in reporting between protocols and publications
were common. When assessing trial manuscripts, journals
should require the trial protocol, and adherence to reporting
guidelines should be ensured.Acknowledgments
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